Game On: Revance Therapeutics Initiates Phase 3 Trial of Topical Botox
Will Revance's RT001 be the first topically neurotoxin treatment?
Tag: Revance
All
PopularAll
Latest
FDA Approves RHA Filler for Midface Contour Deficiencies
The approval covers cheek augmentation and age-related midface contour deficiencies, supported by phase III clinical trial data.
All
Latest
salesMD Targets Patient Follow-Up Gaps in Aesthetic Practices
salesMD provides a patient coordination and lifecycle management service aimed at addressing follow-up gaps that can lead to lost revenue in aesthetic practices.
Studies of DaxibotulinumtoxinA Injection to Treat Forehead Lines and Crow’s Feet Produce Positive Results, Revance Announces
Revance Therapeutics Incannounces results for two Phase 2a open-label, dose escalation studies of its investigational drug candidate DaxibotulinumtoxinA for Injection in the treatment of dynamic forehead lines (FHL) following glabellar (frown) line injections and lateral canthal lines (LCL), commonly known as crow’s feet.
Read More
Revance and Mylan to Advance Development Program for Biosimilar to BOTOX
Revance Therapeutics Inc and Mylan NV announce Mylan’s decision to move forward with a development plan, under a 351(k) pathway, for a proposed biosimilar to BOTOX and BOTOX Cosmetic (onabotulinumtoxinA), according to a media release.
Read MoreRevance Therapeutics Inc Announces Study Results and a License Agreement for RT002
Revance Therapeutics Inc, a Newark, Calif-based developer of neuromodulators for the treatment of aesthetic and therapeutic conditions, announces two pieces of company news regarding RT002.
Read MoreHot Stuff: November 2015
JUVEDERM ULTRA XC for lips and Coolscupting’s new Coolmini for the double chin are among November’s “Hot Stuff.”
Read More